Literature DB >> 8776313

Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

F Saillour1, F Dabis, M Dupon, D Lacoste, P Trimoulet, P Rispal, E Monlun, J M Ragnaud, P Morlat, J L Pellegrin, H Fleury, P Couzigou.   

Abstract

OBJECTIVE: To evaluate the prevalence of antibodies to hepatitis C virus and serological markers for hepatitis B virus infection in patients with HIV.
DESIGN: Cross sectional survey.
SETTING: Aquitaine, southwestern France, 1991-94.
SUBJECTS: 1935 HIV positive patients seen at least once since June 1991. MAIN OUTCOME MEASURES: Presence of antibodies to hepatitis C virus were detected by second or third generation enzyme linked immunosorbent assay (ELISA) and recombinant immunoblot assay (RIBA) and markers for hepatitis B virus detected by ELISA.
RESULTS: The prevalence was 42.5% (823) for antibodies to hepatitis C virus, 56.4 (507) for antibodies to hepatitis B core antigen, 6.9% (133) for hepatitis B surface antigen, 30.2% (584) for antibodies to hepatitis B core and surface antigen with no detectable surface antigen, 26.2% (507) for antibodies to core antigen only, and 4.8% (92) for antibodies to surface antigen only. The prevalence of antibodies to hepatitis C virus was 86.1% (726/843) in subjects who had bloodborne HIV infection and 7.3% (66/899) in those with sexually acquired infection. The prevalence of markers for hepatitis B was higher among homosexuals than in the other groups of patients, except for antibodies to surface antigen alone. The relation between markers for hepatitis B and hepatitis C virus was negative among men but positive among women.
CONCLUSIONS: The results favour the hypothesis that hepatitis C virus is sexually transmitted much less commonly than either HIV or hepatitis B virus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8776313      PMCID: PMC2351885          DOI: 10.1136/bmj.313.7055.461

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  16 in total

1.  [Seroprevalence of viral hepatitis C in patients with human immunodeficiency virus infection].

Authors:  J Ladner; G Brossard; F Dabis; P Morlat; A M Rogues
Journal:  Presse Med       Date:  1992-02-08       Impact factor: 1.228

2.  The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.

Authors:  T L Fong; A M Di Bisceglie; J G Waggoner; S M Banks; J H Hoofnagle
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

3.  Prevalence of antibody to hepatitis C virus in patients infected with the human immunodeficiency virus.

Authors:  K E Sherman; S Freeman; S Harrison; L Andron
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

4.  Hospital-based surveillance of HIV infection: Bordeaux, France, 1983-1990. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA)

Authors:  F Dabis; G Chêne; R Salamon; P Msellati; B Etcheverry
Journal:  AIDS       Date:  1991-06       Impact factor: 4.177

5.  Hepatitis B surface antigen (HBsAg) and antibody to HBsAg. Prevalence in homosexual and heterosexual men.

Authors:  D E Dietzman; J P Harnisch; C G Ray; E R Alexander; K K Holmes
Journal:  JAMA       Date:  1977-12-12       Impact factor: 56.272

6.  Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay.

Authors:  S Kleinman; H Alter; M Busch; P Holland; G Tegtmeier; M Nelles; S Lee; E Page; J Wilber; A Polito
Journal:  Transfusion       Date:  1992 Nov-Dec       Impact factor: 3.157

7.  A comparison between one first generation and three second generation anti-HCV ELISAs: an investigation in high- and low-risk subjects in correlation with recombinant immunoblot assay and polymerase chain reaction.

Authors:  L Bååth; A Widell; E Nordenfelt
Journal:  J Virol Methods       Date:  1992-12-01       Impact factor: 2.014

8.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

9.  Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection.

Authors:  I S Sheen; Y F Liaw; C M Chu; C C Pao
Journal:  J Infect Dis       Date:  1992-05       Impact factor: 5.226

Review 10.  Hepatitis C: natural history of a unique infection.

Authors:  S Iwarson; G Norkrans; R Wejstål
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

View more
  8 in total

1.  Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1.

Authors:  E A Santos; C F T Yoshida; V C Rolla; J M Mendes; I F Vieira; J Arabe; S A Gomes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-18       Impact factor: 3.267

Review 2.  Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 3.  Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection.

Authors:  Greg L Plosker; Gillian M Keating
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century.

Authors:  Vincent Lo Re; Jay R Kostman; Valerianna K Amorosa
Journal:  Clin Liver Dis       Date:  2008-08       Impact factor: 6.126

5.  Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years.

Authors:  Helen M Chun; Ann M Fieberg; Katherine Huppler Hullsiek; Alan R Lifson; Nancy F Crum-Cianflone; Amy C Weintrob; Anuradha Ganesan; Robert V Barthel; William P Bradley; Brian K Agan; Michael L Landrum
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

Review 6.  Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.

Authors:  Sarah M McCabe; Qing Ma; Judianne C Slish; Linda M Catanzaro; Neha Sheth; Robert DiCenzo; Gene D Morse
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients.

Authors:  Monica Schiavini; Elena Angeli; Annalisa Mainini; Caterina Uberti-Foppa; Pietro Zerbi; Caterina Sagnelli; Antonietta Cargnel; Gianluca Vago; Pier Giorgio Duca; Riccardo Giorgi; Giuliano Rizzardini; Guido Gubertini
Journal:  Hepat Mon       Date:  2011-07-01       Impact factor: 0.660

8.  Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.

Authors:  Eneida A Santos; Michel V F Sucupira; Juçara Arabe; Selma A Gomes
Journal:  BMC Infect Dis       Date:  2004-08-31       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.